Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5802-5808. doi: 10.1016/j.bmcl.2016.10.023. Epub 2016 Oct 12.

Abstract

Targeting the IL17 pathway and more specifically the nuclear receptor RORγ is thought to be beneficial in multiple skin disorders. The Letter describes the discovery of phenoxyindazoles and thiophenoxy indazoles as potent RORγ inverse agonists. Optimization of the potency and efforts to mitigate the phototoxic liability of the series are presented. Finally, crystallization of the lead compound revealed that the series bound to an allosteric site of the nuclear receptor. Such compounds could be useful as tool compounds for understanding the impact of topical treatment on skin disease models.

Keywords: Allosteric; Inverse agonists; Phototoxicity; ROR gamma; Topical administration.

MeSH terms

  • Drug Inverse Agonism
  • Humans
  • Indazoles / chemistry*
  • Indazoles / pharmacology*
  • Molecular Docking Simulation
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / agonists*
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / metabolism
  • Structure-Activity Relationship

Substances

  • Indazoles
  • Nuclear Receptor Subfamily 1, Group F, Member 3